Chimeric Therapeutics Ltd
CHM
Company Profile
Business description
Chimeric Therapeutics Ltd is a biotechnology company engaged in developing a cancer cell therapy drug. Its technology CLTX-CAR T uses chlorotoxin, a peptide discovered in scorpion venom, as the tumor-targeting component of the CAR to reprogram T cells. Primary products under development by the company are NK Cell Derived Allogenic Therapies and T Cell Derived Autologous Therapies. The company has one segment being the research, development and commercialization of health technologies.
Contact
62 Lygon Street
Level 3, Carlton South
MelbourneVIC3053
AUST: +61 398245254
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
30 June 2025
Employees
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,779.90 | 5.10 | 0.06% |
| CAC 40 | 7,597.40 | 18.59 | -0.24% |
| DAX 40 | 23,545.56 | 96.02 | -0.41% |
| Dow JONES (US) | 43,089.02 | 507.24 | 1.19% |
| FTSE 100 | 8,754.62 | 4.37 | -0.05% |
| HKSE | 24,474.67 | 297.60 | 1.23% |
| NASDAQ | 19,912.53 | 281.56 | 1.43% |
| Nikkei 225 | 38,942.07 | 151.51 | 0.39% |
| NZX 50 Index | 12,460.96 | 6.52 | -0.05% |
| S&P 500 | 6,092.18 | 67.01 | 1.11% |
| S&P/ASX 200 | 8,559.20 | 3.70 | 0.04% |
| SSE Composite Index | 3,455.97 | 35.41 | 1.04% |